Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
A83-01 (HB3218)
Description:Selective TGF-βRI (ALK5), ALK4 and ALK7 inhibitor. Maintains human hiPSC self renewal, 3D growth matrix component and promotes long-term organoid growth. Aids fibroblast to NSC/cardiomyocyte reprogramming.
Purity:>98%
Fasudil hydrochloride (HB0283)
Description:ROCK and cyclic nucleotide-dependent protein kinase inhibitor
Purity:>98%
HA 1100 hydrochloride (HB2293)
Description:Selective, reversible, cell-permeable ROCK inhibitor
Purity:>99%
Imatinib mesylate (HB1943)
Description:Tyrosine kinase inhibitor that targets BCR‑ABL, c‑KIT, and PDGFR kinases
Purity:>98%
ITD 1 (HB3446)
Description:Selective TGF-β signaling inhibitor. Induces cardiomyocyte differentiation in ESCs.
Purity:>98%